Feasibility and Toxicity of Weekly Paclitaxel-Carboplatin in 131 Patients with Pretreated and Non-Pretreated Solid Tumors

Publisher： Karger

E-ISSN： 2296-5262|25|2|152-157

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.25, Iss.2, 2002-05, pp. : 152-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

By  

Oncology, Vol. 77, Iss. 6, 2009-12 ,pp. : 349-357

Karger

Access to resources Recommend Favorite

Paclitaxel in Cisplatin or Carboplatin-Pretreated Ovarian Cancer

By  

Oncology, Vol. 55, Iss. 3, 1998-04 ,pp. : 228-234

Karger

Access to resources Recommend Favorite

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 73, Iss. 5-6, 2008-06 ,pp. : 407-414

Karger

Access to resources Recommend Favorite

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

By Kellum A.   Jagiello-Gruszfeld A.   Bondarenko I.N.   Patwardhan R.   Messam C.   Mostafa Kamel Y.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2339-2346

Informa Healthcare

Access to resources Recommend Favorite